This site is intended for US Healthcare Professionals

Sign Up for Updates
Sign Up for Updates
Sign Up for Updates
How to Prescribe

XDEMVY gives you might over mites to eradicate Demodex blepharitis (DB)1,2

XDEMVY is designed to effectively and safely target, paralyze, and kill Demodex mites1 Get Your Patients Started

Demodex blepharitis is very common3.4

of eye care patients in the US — that’s approximately 25 million patients3,4

Discover More on DB

*STUDY DESIGN: A retrospective chart review for DB by 7 investigators at 6 eye care clinics of the case records of patients (N=1032) who underwent a slit lamp examination, regardless of chief complaint.3

How XDEMVY works

Lotilaner, the active ingredient in XDEMVY, is a lipophilic agent in an aqueous drop† that acts specifically via mite GABA-gated chloride channels to target, paralyze, and kill Demodex mites.1,5,6

Learn More

 GABA=gamma-aminobutyric acid.
†Preserved with potassium sorbate.

REAL XDEMVY RESULTS

IMAGE CREDIT
Paul Karpecki, OD
IMAGE CREDIT
Vin Dang, OD
IMAGE CREDIT
Paul Singh, MD
IMAGE CREDIT
Paul Karpecki, OD
IMAGE CREDIT
Vin Dang, OD
IMAGE CREDIT
Syed Hussain, MD
IMAGE CREDIT
Jessie Ustick, OD
IMAGE CREDIT
Jaclyn Garlich, OD
IMAGE CREDIT
Edward Yung, MD
IMAGE CREDIT
Paul Karpecki, OD
IMAGE CREDIT
Paul Singh, MD
IMAGE CREDIT
Paul Karpecki, OD
IMAGE CREDIT
Mile Brujic, OD
IMAGE CREDIT
Amr Kouchouk, MD
IMAGE CREDIT
Ben Gaddie, OD
IMAGE CREDIT
Vin Dang, OD
IMAGE CREDIT
Justin Schweitzer, OD
IMAGE CREDIT
Darrell Pennell, MD
IMAGE CREDIT
Vin Dang, OD
IMAGE CREDIT
Laura Periman, MD
IMAGE CREDIT
Joshua Davidson, OD
IMAGE CREDIT
Justin Schweitzer, OD
IMAGE CREDIT
Neda Shamie, MD
IMAGE CREDIT
Selina McGee, OD
IMAGE CREDIT
Vin Dang, OD
IMAGE CREDIT
Marc Bloomenstein, OD
IMAGE CREDIT
Paul Karpecki, OD
IMAGE CREDIT
Vin Dang, OD
IMAGE CREDIT
Paul Singh, MD
IMAGE CREDIT
Paul Karpecki, OD
IMAGE CREDIT
Vin Dang, OD
IMAGE CREDIT
Syed Hussain, MD
IMAGE CREDIT
Jessie Ustick, OD
IMAGE CREDIT
Jaclyn Garlich, OD
IMAGE CREDIT
Edward Yung, MD
IMAGE CREDIT
Paul Karpecki, OD
IMAGE CREDIT
Paul Singh, MD
IMAGE CREDIT
Paul Karpecki, OD
IMAGE CREDIT
Mile Brujic, OD
IMAGE CREDIT
Amr Kouchouk, MD
IMAGE CREDIT
Ben Gaddie, OD
IMAGE CREDIT
Vin Dang, OD
IMAGE CREDIT
Justin Schweitzer, OD
IMAGE CREDIT
Darrell Pennell, MD
IMAGE CREDIT
Vin Dang, OD
IMAGE CREDIT
Laura Periman, MD
IMAGE CREDIT
Joshua Davidson, OD
IMAGE CREDIT
Justin Schweitzer, OD
IMAGE CREDIT
Neda Shamie, MD
IMAGE CREDIT
Selina McGee, OD
IMAGE CREDIT
Vin Dang, OD
IMAGE CREDIT
Marc Bloomenstein, OD

An average of 50% of patients taking XDEMVY achieved a significant improvement in their eyelids (reduction of collarettes to no more than 2 collarettes per upper lid) at Day 43 vs 10% taking vehicle across 2 combined clinical trials (SATURN-1 and SATURN-2; XDEMVY: N=402, vehicle: N=404).7 All images are of real patients diagnosed with Demodex blepharitis.

Results after full 6 weeks of treatment.
Results may vary.

Get the info you need to send Demodex mites packing

Sign Up for Updates

Check out these upcoming events!Events Page

References: 1. XDEMVY [prescribing information]. Tarsus Pharmaceuticals, Inc; 2023. 2. Gao YY, Di Pascuale MA, Li W, et al. High prevalence of Demodex in eyelashes with cylindrical dandruff. Invest Ophthalmol Vis Sci. 2005;46(9):3089-3094. 3. Trattler W, Karpecki P, Rapoport Y, et al. The prevalence of Demodex blepharitis in US eye care clinic patients as determined by collarettes: a pathognomonic sign. Clin Ophthalmol. 2022;16:1153-1164. 4. O’Dell L, Dierker DS, Devries DK, et al. Psychosocial impact of Demodex blepharitis. Clin Ophthalmol. 2022;16:2979-2987. 5. Toutain CE, Seewald W, Jung M. The intravenous and oral pharmaco-kinetics of lotilaner in dogs. Parasit Vectors. 2017;10:522. 6. Yeu E, Wirta DL, Karpecki P, Baba SN, Holdbrook M; Saturn I Study Group. Lotilaner ophthalmic solution, 0.25%, for the treatment of Demodex blepharitis: results of a prospective, randomized, vehicle-controlled, double-masked, pivotal trial (Saturn-1). Cornea. 2022;42:435-443. 7. Yeu E, Mun J, Vollmer P, et al. Treatment of Demodex blepharitis with lotilaner ophthalmic solution. 0.25%: combined analysis of two pivotal randomized, vehicle-controlled, multicenter trials. Saturn-1 and Saturn-2 combined data. Presented at: ARVO 2023; April 23-27, 2023; New Orleans, LA.

INDICATIONS AND USAGE
XDEMVY (lotilaner ophthalmic solution) 0.25% is indicated for the treatment of Demodex blepharitis.

IMPORTANT SAFETY INFORMATION:

WARNINGS AND PRECAUTIONS

Risk of Contamination: Do not allow the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to minimize contamination of the solution. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.

Use with Contact Lenses: XDEMVY contains potassium sorbate, which may discolor soft contact lenses. Contact lenses should be removed prior to instillation of XDEMVY and may be reinserted 15 minutes following its administration.

ADVERSE REACTIONS: The most common adverse reaction with XDEMVY was instillation site stinging and burning which was reported in 10% of patients. Other ocular adverse reactions reported in less than 2% of patients were chalazion/hordeolum and punctate keratitis.

To report SUSPECTED ADVERSE REACTIONS, contact Tarsus Pharmaceuticals, Inc. at 1-888-421-4002 or the FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

Please see full Prescribing Information.

INDICATIONS AND USAGE
XDEMVY (lotilaner ophthalmic solution) 0.25% is indicated for the treatment of Demodex blepharitis.

IMPORTANT SAFETY INFORMATION:

WARNINGS AND PRECAUTIONS

Risk of Contamination: Do not allow the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to minimize contamination of the solution. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.